COR Price Prediction Next Week
Based on the provided search results and context, here's the analysis for COR (Cencora Inc.) for the next trading week:
Technical Analysis
The stock is showing strong momentum with an 8.4% YTD gain in 2025, outperforming the S&P 500's 2.9% increase. Recent price action shows consolidation near $244-245 levels with support at $230 and resistance at $250 based on options activity.
Fundamental Drivers
- Strong Q4 earnings beat with revenue up 12.8% YoY to $81.49B
- Management raised FY2025 adjusted EPS guidance by 3% to $15.40
- Consistent earnings beats in last 4 quarters showing operational strength
Analyst Sentiment
Wall Street maintains a "Strong Buy" consensus:
- 11 Strong Buy ratings
- 4 Hold ratings
- Mean price target: $282.14 (15.8% upside)
- Street high target: $307 (26% upside)
Price Projection for Next Week Based on technical indicators and recent momentum:
- Support level: $230
- Resistance level: $250
- Expected trading range: $242-248
Trading Recommendation BUY with target price of $250 for next week based on:
- Strong fundamental growth trajectory
- Positive analyst consensus
- Technical support at current levels
- Options market positioning suggesting upward bias
Set stop loss at $230 to limit downside risk.
COR Similar Chart Price Prediction
The price of COR is predicted to go up -18.43%, based on the high correlation periods with CECO. The similarity of these two price pattern on the periods is 95.27%.
COR
CECO
Down: -18.43%Similarity: 95.27%
COR Revenue Forecast
COR EPS Forecast
COR FAQs
What is COR revenue forecast for next quarter？
What is COR eps forecast for next quarter？
COR VS S&P500
Cencora distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.
A robust demand for GLP-1s (diabetes drug) provides a strong tailwind to Cencora's top line and allows the distributor to offer other high-margin services to both manufacturers and customers.
Technology advancements continue to improve Cencora's performance and present new opportunities for wholesalers.
COR Analyst's Forecast
Eric Luebchow
Wells Fargo
Hold
2024-12-13
Price Target
$249 → $237
Upside
+2.05%
Wells Fargo lowered the firm's price target on Cencora to $237 from $249 and keeps an Equal Weight rating on the shares. The firm updated estimates and price targets for the drug distribution group following the results and recent mergers. It is "generally constructive" on core distribution fundamentals into 2025, but says valuations and overhangs leave it neutral across the group.
David Rodgers
Baird
Buy
2024-11-07
Price Target
$287 → $292
Upside
+17.83%
Kevin Caliendo
UBS
Strong Buy
2024-11-07
Price Target
$275 → $285
Upside
+15%
